Immunotherapy has revolutionized colon cancer treatment. Immune checkpoint inhibitors
(ICIs) have shown clinical benefits for colon cancer patients, especially those with high …

Purpose Recent years have seen a change in the way that clinical trials are being
conducted. There has been a rise of designs more flexible than traditional adaptive and …

Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …

Cancers arising from germline DNA mismatch repair deficiency or polymerase proofreading
deficiency (MMRD and PPD) in children harbour the highest mutational and microsatellite …

High-grade meningiomas are associated with neuro-cognitive morbidity and have limited
treatments. High-grade meningiomas harbor an immunosuppressive tumor …

Checkpoint inhibitors (CPI) have revolutionized the treatment paradigm for advanced solid
tumors; however, there remains an opportunity to improve response rates and outcomes. In …

Abstract Type I interferons (IFN-Is) are central regulators of anti-tumor immunity and
responses to immunotherapy, but they also drive the feedback inhibition underlying …

Simple Summary Immune checkpoint inhibitors (ICIs) have been investigated in epithelial
ovarian cancer in first-line and recurrent settings. When used as a single agent or in …

Original research: An open-label, phase II multicohort study of an oral hypomethylating agent
CC-486 and durvalumab in advanced solid tumors - PMC Back to Top Skip to main content …

Melanoma is the most aggressive form of skin cancer, representing approximately 4% of all
cutaneous neoplasms it accounts for up to 80% of deaths. Advanced stages of melanoma …